Cortes, Jorge E.
Jiang, Qian
Wang, Jianxiang http://orcid.org/0000-0001-9437-9151
Weng, Jianyu
Zhu, Huanling
Liu, Xiaoli
Hochhaus, Andreas
Kim, Dong-Wook
Radich, Jerald
Savona, Michael
Martin-Regueira, Patricia
Sy, Oumar
Gurnani, Renuka
Saglio, Giuseppe
Funding for this research was provided by:
Bristol Myers Squibb
Article History
Received: 18 November 2019
Revised: 6 March 2020
Accepted: 13 March 2020
First Online: 7 April 2020
Compliance with ethical standards
:
: JEC has served as a consultant to and received research funding from Bristol Myers Squibb, Novartis, Pfizer, and Takeda. QJ, JyW, HZ, and XL declare no conflicts to disclose. AH has received research funding from Bristol Myers Squibb, Incyte, Novartis, Pfizer, and Takeda. DWK has received research funding from Bristol Myers Squibb, IIyang, Novartis, and Pfizer. JR has served as a consultant to Bristol Myers Squibb, Novartis, Pfizer, and Takeda, and has received research funding from Novartis. JxW has received research funding from Celgene. MS has served as a consultant to, or served on the board of directors/advisors of Abbvie, Celgene, Incyte, Karyopharm, and Takeda, and received funding from Takeda and holds equity ownership in Karyopharm. PMR is an employee and holds equity ownership with Bristol Myers Squibb. OS and RG are employees of Bristol Myers Squibb. GS has served as a consultant to Ariad, Bristol Myers Squibb, Incyte, Novartis, and Pfizer.